News
🇺🇸 AmericasLatest pharmaceutical news, drug approvals, and FDA regulatory updates
Latest News
FDA Launches Manufacturing PreCheck Pilot Program to Streamline Drug Production Oversight
FDA's new PreCheck pilot program aims to modernize manufacturing inspections through risk-based approaches, potentially reducing regulatory burden.
Real-World Evidence Transforms Drug Development as FDA Expands Regulatory Framework
Real-world data and evidence are reshaping pharmaceutical decision-making following the 21st Century Cures Act, offering new pathways for drug approval.
FDA Releases Updated Database of Untitled Letters for Pharmaceutical Marketing Violations
The FDA's CDER Freedom of Information Office has updated its database of untitled letters targeting pharmaceutical promotional violations.
FDA Approves Higher-Dose Wegovy 7.2mg for Weight Loss Under Priority Review Program
Novo Nordisk's Wegovy receives FDA approval for 7.2mg dose under National Priority Voucher Program, expanding treatment options for adult obesity patients.
FDA Approves First Treatment for Neurologic Symptoms of Hunter Syndrome
The FDA has approved Avlayah (tividenofusp alfa-eknm) as the first treatment specifically targeting neurologic manifestations of Hunter syndrome.
FDA Approves Kresladi: First Gene Therapy for Rare Immune Disorder LAD-I Marks Medical Breakthrough
FDA approves Kresladi (marnetegragene autotemcel), the first gene therapy for severe Leukocyte Adhesion Deficiency Type I, offering hope for ultra-rare disease.
FDA Approves Foundayo's Orforglipron as First New Molecular Entity Under Priority Voucher Program
FDA approves Foundayo's orforglipron, marking the fifth approval under the Commissioner's National Priority Voucher pilot program for expedited review.
FDA Approves SkinGuard: New Topical Treatment for Severe Eczema
The FDA has approved SkinGuard, a groundbreaking topical treatment for severe eczema, promising significant relief and enhanced quality of life for patients.
FDA Approves CogniMax: New Early-Stage Alzheimer's Treatment
CogniMax has received FDA approval as a new treatment for early-stage Alzheimer's, promising to enhance cognitive function and improve quality of life.
FDA Approves VitaRestore: New Treatment for Age-Related Macular Degeneration
The FDA has officially approved VitaRestore, a new treatment designed to combat age-related macular degeneration, potentially transforming patient care.
FDA Approves NasoClear: First Nasal Spray for Pediatric RSV
The FDA has approved NasoClear, marking it as the first nasal spray specifically designed for treating pediatric RSV, providing hope for affected children and their families.
FDA Approves Revitalize: Breakthrough for Chronic Fatigue Syndrome
Revitalize has received FDA approval as a revolutionary treatment for Chronic Fatigue Syndrome, promising significant improvements in patients' quality of life.
FDA Approves GeneCorrect: GeneTech's Breakthrough Cystic Fibrosis Therapy
GeneTech's GeneCorrect has received FDA approval, marking a significant advancement in the treatment of cystic fibrosis and improving patient outcomes.
FDA Approves MyoRepair: Breakthrough Therapy for Heart Failure
The FDA has approved MyoRepair, a groundbreaking therapy for heart failure, marking a significant advancement in treatment options for patients.
FDA Approval OncoBlock: Accelerated Approval for Refractory AML
The FDA has granted accelerated approval for OncoBlock, a promising new treatment for patients with refractory acute myeloid leukemia (AML).
FDA Approves Xylocor: Novel Advanced Melanoma Treatment by Xylos Bio
Xylos Bio's Xylocor receives FDA approval as a novel treatment for advanced melanoma, marking a significant advancement in cancer therapy.
FDA Approves Repatha: Key Details on Amgen's Cardiovascular Drug
Repatha, recently approved by the FDA, is a groundbreaking treatment by Amgen for cardiovascular disease, targeting high cholesterol effectively.
FDA Approves Tecentriq for Extensive-Stage Small Cell Lung Cancer
The FDA has granted approval for Tecentriq, a groundbreaking treatment for extensive-stage small cell lung cancer, enhancing options for patients in need.
FDA Approves Opdivo for Advanced Renal Cell Carcinoma
The FDA has approved Opdivo for the treatment of advanced renal cell carcinoma, marking a significant advancement in cancer therapy options for patients.
FDA Approves Keytruda for Adjuvant Treatment of Stage III Melanoma
The FDA has granted approval for Keytruda as an adjuvant treatment for patients with Stage III melanoma, marking a significant advancement in cancer therapy.